Creating natural product diversity via the fabrication of a hybrid fatty acid-nonribosomal peptide synthetase
Creating natural product diversity via the fabrication of a hybrid fatty acid-nonribosomal peptide synthetase
批准号:
10339399
负责人:
Joshua Catungal Corpuz
金额:
$1.99万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-01 至 2022-04-29
关键词:
AchievementAddressAmino AcidsAnabolismAntibioticsAntifungal AgentsBerryBiochemistryBiomedical EngineeringCarrier ProteinsChemicalsClinicComplexComputational BiologyComputer ModelsComputing MethodologiesCouplingDaptomycinDataDevelopmentDrug TargetingEngineeringEnzymesEscherichia coliFatty AcidsFatty-acid synthaseFutureGoalsHybridsImmunosuppressive AgentsIn VitroKnowledgeMethodologyMethodsMicrobeModelingModernizationModificationMolecularMonitorMovementMultiple PartnersMutagenesisNatural ProductsNatureOrganismPathway interactionsPeptide BiosynthesisPeptidesPharmaceutical PreparationsPrevalenceProdigiosinProductionProductivityProteinsRoleSpecificityStructureSystemTherapeuticTrainingWorkX-Ray Crystallographyantimicrobialclinically relevantcombinatorialdesigngenetic technologygenome sequencingholo-(acyl-carrier-protein) synthasein vivomethicillin resistant Staphylococcus aureusmicrobialnovelpeptide synthasepolyketide synthasepractical applicationprogramsprotein complexprotein protein interactionrational designscaffoldsimulationstructural biologysuccesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract: Natural products and derivatives/mimics of natural products make up the majority of modern
therapeutic drugs due to their unique complex organic scaffolds that contribute to their wide range of bioactivities.
These natural products are synthesized by the fatty acid synthase (FAS), the nonribosomal peptide synthetase
(NRPS) or the polyketide synthase (PKS). This program studies the role of protein•protein interactions in the
modular synthases responsible for the formation of clinically relevant fatty acids and nonribosomal peptides for
the long-term goal of re-designing and completely controlling the biosynthetic assembly lines. An example of a
natural product therapeutic in the clinic is the antimicrobial daptomycin, which is a lipopeptide synthesized from
a hybrid fatty acid synthase (FAS) and nonribosomal peptide synthetase (NRPS) that is used to treat methicillin-
resistant Staphylococcus aureus. Thus, the hybrid FAS/NRPS are valuable systems to study and control so we
may diversify natural products with new or enhanced bioactivities. Over the last three decades, true control over
the biosynthetic assembly lines has remained elusive; the lack of a fundamental understanding on how the mega-
synthase’s protein•protein interactions govern natural product biosynthesis has hindered this promising advance.
In order to control and develop a hybrid FAS/NRPS biosynthetic pathway, first we must understand the
fundamentals that guides the related biosynthetic machinery. Both FASs and NRPSs are dependent on the
carrier protein (CP); the CP shuttles the growing substrate between multiple partner proteins (PP) for
functionalization and incorporation into the natural product. The modular nature of fatty acid and nonribosomal
peptide biosynthesis is conserved among organisms, however, the mechanism of CP•PP recognition in each
pathway is distinct. Thus, to re-design these biosynthetic assembly lines, this project focuses on studying the
molecular details of the CP•PP interface. We aim to 1) Characterize NRPS CP•PP interactions via X-ray
crystallography, 2) establish a computational methodology to design a hybrid NRPS/FAS interaction, and 3)
explore the cross-pathway productivity of the hybrid NRPS/FAS interaction. The results from these studies will
be integral to the future bioengineering of these modular synthases.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.synbio.2022.02.006
发表时间:
2022-06
期刊:
Synthetic and systems biotechnology
影响因子:
4.8
作者:
[Corpuz JC, Sanlley JO, Burkart MD]
通讯作者:
Burkart MD
海外基金